Consensus Replimune Group, Inc.

Equities

REPL

US76029N1063

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
6.42 ^USD	+4.39%		-0.47%	-23.84%

Apr. 08	Replimune Group Provides Interim Results for Skin Cancer Therapy	MT
Mar. 26	Replimune Group, Inc. Announces Management Changes	CI

Evolution of the average Target Price on Replimune Group, Inc.

Price target over the last 5 years

History of analyst recommendation changes

cfa3400584eecbf5d30fe20a84ed1e96.n72bp_A-hk1XBck2cmYvDjOzelWp1jPtYNlqoSMeoFk.y8T0xscJwz82UJBUOxVtREn_SDCe5QqjMukM42EzxAHI6MnoiUq1OD9pmA~2f923d423b5a6600a92212ca3dd2b69c

Analyst Recommendations on Replimune Group, Inc.

Wedbush Raises Replimune Group's PT to $16 From $14 After Adjusting Financing Assumptions, Keeps Outperform Rating	Feb. 09	MT
Wedbush Cuts Replimune Group's PT to $14 From $52 After Narrow Complete Response Rate Miss in Phase 2 Trial of Skin Cancer Treatment Candidate; Keeps Outperform Rating	Dec. 06	MT
Barclays Lowers Price Target on Replimune Group to $13 From $50, Keeps Overweight Rating	Dec. 06	MT
JPMorgan Adjusts Replimune Price Target to $38 From $42, Maintains Overweight Rating	Nov. 24	MT
HC Wainwright Adjusts Price Target on Replimune Group to $50 From $51, Keeps Buy Rating	23-08-07	MT
JPMorgan Adjusts Price Target on Replimune to $50 From $38, Maintains Overweight Rating	23-06-15	MT
HC Wainwright Raises Price Target on Replimune Group to $51 From $50, Keeps Buy Rating	23-06-05	MT
Piper Sandler Assumes Replimune Group at Overweight With $44 Price Target	23-04-17	MT
HC Wainwright Adjusts Replimune Group's Price Target to $50 From $48, Maintains Buy Rating	23-02-10	MT
EF Hutton Starts Replimune Group at Buy With $60 Price Target	23-01-05	MT
BMO Capital Adjusts Replimune Group's Price Target to $70 From $40, Keeps Outperform Rating	22-12-12	MT
HC Wainwright Adjusts Price Target on Replimune to $48 From $60, Maintains Buy Rating	22-11-04	MT
BMO Capital Adjusts Replimune Group's Price Target to $40 From $30, Keeps Outperform Rating	22-10-14	MT
SVB Securities Adjusts Replimune Group's Price Target to $30 From $37, Reiterates Outperform Rating	22-10-03	MT
Piper Sandler Trims Replimune Group's Price Target to $43 From $44, Reiterates Overweight Rating	22-08-17	MT
SVB Securities Trims Lowers Replimune Group's Price Target to $37 From $48, Maintains Outperform Rating	22-08-05	MT
Wedbush Adjusts Replimune Group's Price Target to $52 From $59, Keeps Outperform Rating	22-05-24	MT
SVB Securities Trims Replimune Group's Price Target to $48 From $49, Keeps Outperform Rating	22-05-20	MT
JPMorgan Lowers Replimune Group's Price Target to $39 From $47, Maintains Overweight Rating	22-04-04	MT
BMO Capital Adjusts Replimune Group's Price Target to $30 From $51, Keeps Outperform Rating	22-03-18	MT
Piper Sandler Initiates Coverage of Replimune Group With Overweight Rating	21-11-18	MT
REPLIMUNE : SVB Leerink Adjusts Price Target on Replimune to $49 From $55, Maintains Outperform Rating	21-08-23	MT
REPLIMUNE : Chardan Suspends Coverage on Replimune at Buy Rating With $48 Price Target	21-08-02	MT
Replimune Group, Inc. Announces Plans to Amend CERPASS Clinical Trial Protocol to Add Complete Response Rate as an Additional Independent Primary Endpoint	21-05-20	CI
REPLIMUNE : Wedbush Adjusts Replimune Group's Price Target to $59 From $54, Keeps Outperform Rating	21-02-08	MT